Navigation Links
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Date:7/24/2009

KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia.

Negative symptoms of schizophrenia include apathy, lack of emotion and poor social functioning, among others. In the study, these symptoms were assessed using the validated 16-item Negative Symptom Assessment scale (NSA-16).

"These symptoms are among the most difficult to treat in the schizophrenia spectrum," said Armin Szegedi, M.D., Ph.D., vice president, global clinical research, central nervous system, Schering-Plough Research Institute. "Few studies with the antipsychotics currently available on the market have been designed specifically to evaluate long-term effects on predominant, persistent negative symptoms. The results from this large clinical study program will provide new insights into potential treatment of these symptoms."

In the study, SAPHRIS was significantly more effective than olanzapine in the reduction of negative symptoms as measured by change from baseline to Day 365 in the NSA-16 total score, the primary endpoint of the study. By using a mixed model for repeated measures (MMRM), least square mean changes in the NSA-16 total score were -15.8 for SAPHRIS vs. -11.0 for olanzapine (P=0.015). Full results of the trial, including efficacy, safety and tolerability data, will be submitted for presentation at a medical meeting at a later date.

These results follow those of a previously reported clinical trial in this patient population using the same study design and protocol in which both asenapine and olanzapi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
2. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
5. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
6. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
9. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
10. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
11. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
(Date:3/3/2015)... March 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, ... in Miami.   The live presentation takes ... PT).  The presentation will be webcast and may be ... Listeners are encouraged to visit the ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... , March 3, 2015  Thingee Corporation, a ... be delivering a presentation entitled, "Technology Adoption: Making Reps, ... Thriving through Innovations and Technology ,  in ... 11 to 13, 2015. Audiences looking to learn how ... will want to be in the audience for the ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Thingee to present at 11th Annual Synergistix Users Conference 2
... ONTY ) (TSX: ONY) announced today that it ... common stock and warrants to purchase 2,909,244 shares of its ... May 26, 2009. Oncothyreon sold the shares and warrants for ... a warrant to purchase 0.75 shares of common stock). The ...
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... of Research and Development, will be presenting pre-clinical data from ... the American Society of Gene Therapy, which is being held ... from Wednesday, May 27th through to Saturday, May 30th, 2009. ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... for human disease, announced today that the company will be ... programs: LX1031 , an oral drug ... (IBS), and LX1032 , an ...
Cached Biology Technology:Oncothyreon announces closing of $11.1 million registered direct financing 2Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 3Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week 2Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week 3
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... University of New Hampshire researchers will have two new ... of modeling space weather to advance their work, thanks ... grants to the university. The grants, totaling $1.35 million, will ... the Space Science Center in the Institute for the Study ...
... A team of researchers at Michigan State University has documented ... The results, published in the current issue of Nature ... how E. coli bacteria figured out how to ... of citrate. "It,s pretty nifty to see a new ...
... This month, GSA,s top geoscience journal, Geology, has ... include Bhutan; the James Bay Lowland of Canada; Mount ... New Mexico, USA; the Quelccaya Ice Cap, Peru; the ... micro-tunneling, fibrous diamonds, climate change, cosmic rays, and maars. ...
Cached Biology News:UNH labs receive 2 NSF grants totalling $1.35m for research instruments 2Evolution is as complicated as 1-2-3 2GEOLOGY adds 30 new articles online 2GEOLOGY adds 30 new articles online 3GEOLOGY adds 30 new articles online 4GEOLOGY adds 30 new articles online 5GEOLOGY adds 30 new articles online 6GEOLOGY adds 30 new articles online 7GEOLOGY adds 30 new articles online 8GEOLOGY adds 30 new articles online 9GEOLOGY adds 30 new articles online 10GEOLOGY adds 30 new articles online 11GEOLOGY adds 30 new articles online 12GEOLOGY adds 30 new articles online 13GEOLOGY adds 30 new articles online 14GEOLOGY adds 30 new articles online 15GEOLOGY adds 30 new articles online 16GEOLOGY adds 30 new articles online 17GEOLOGY adds 30 new articles online 18GEOLOGY adds 30 new articles online 19GEOLOGY adds 30 new articles online 20GEOLOGY adds 30 new articles online 21GEOLOGY adds 30 new articles online 22GEOLOGY adds 30 new articles online 23
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: